Grace Therapeutics, Inc. Weighted Average Exercise Price Of Share Options Exercised In Share-based Payment Arrangement
Grace Therapeutics, Inc. (GRCE) reported Weighted Average Exercise Price Of Share Options Exercised In Share-based Payment Arrangement of CAD 0.77 for the 12-month period ending 2019-03-31, per its 20-F filed 2019-06-26.
Discontinued › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement · last filed 2019-06-26
| Period end | Weighted Average Exercise Price Of Share Options Exercised In Share-based Payment Arrangement 12 month |
|---|---|
| 2019-03-31 | 0.77 CAD 20-F · filed 2019-06-26 |
| 2016-02-29 | 2.50 CAD 20-F · filed 2018-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |